In this Issue
New concepts in the nonsurgical treatment of retinal diseases.
By Allen C. Ho, MD, Chief Medical Editor; and Robert L. Avery, MD, Associate Medical Editor
BUSINESS OF RETINA
Pennsylvania Avenue Updates
What it is, why it is important, and what it means for physicians.
By Paul Gallogly, MD
Innovations in Retina
Retina specialists are finding that apps are not just for music and games anymore.
By Aron Shapiro
A quick guide to attending educational meetings and conferences as a vitreoretinal surgical fellow.
By Jayanth Sridhar, MD; Yoshihiro Yonekawa, MD; and Daniel Chao, MD, PhD
Coding for Retina
A closer look at the validity of the auditing parameters pertaining to general ophthalmological services—the eye codes—and of the findings as pertains to retina practices that use eye codes exclusively.
By Riva Lee Asbell
Surgical pearls for this complex implantation procedure.
By Lisa C. Olmos de Koo, MD, MBA; and Ninel Z. Gregori, MD
Use of a modified macular buckle improved precision and allowed optimal positioning.
By Matteo Forlini, MD; Małgorzata Szkaradek, MD; Robert Rejdak, MD, PhD; Adriana Bratu, MD; Paolo Rossini, MD; Cesare Forlini, MD; and Gian Maria Cavallini, MD
Recent findings support the combination of pharmacologic and laser therapies for retinal diseases.
By Anat Loewenstein, MD
Although not a replacement for the microscope, the endoscope has an important place in retina surgery.
By S. Chien Wong, MD, FRCSEd (Ophth)
Changing treatment patterns often dictate the need for a change in disease detection.
By Raj K. Maturi, MD
Overcoming imaging challenges in eyes of AMD patients implanted with a telescope can result in high-quality images.
By Anna Pappas, BS, COA; Melanie J. Fortin, BS, COA; and Brian C. Joondeph, MD, MPS
By understanding the mechanisms of a new imaging tool, retina specialists may further appreciate its potential.
By Talisa E. de Carlo, BA; Gregory D. Lee, MD; David R. Lally, MD; and Jay S. Duker, MD
SPECIAL FOCUS: OCULAR ONCOLOGY
Genomic analysis can help to personalize treatment and lead to better outcomes.
By Aaron S. Gold, OD; Victor M. Villegas, MD; Andrea Wildner, CRA; Jennifer Thomson, CRA; Fiona J. Ehlies, BSc, CDOS; and Timothy G. Murray, MD, MBA, FACS
Several different vascular tumors can occur in the retina, each with its own features and findings.
By Carol L. Shields, MD; Alexzandra Douglass, BS; Timothy Higgins, BS; Wasim A. Samara, MD; and Jerry A. Shields, MD
The options for focal treatment of retinoblastoma are growing. Here is a rundown of the latest options and what the latest studies reveal.
By Victor M. Villegas, MD; Aaron S. Gold, OD; Andrea Wildner, CRA; Jennifer Thomson, CRA; Fiona J. Ehlies, BSc, CDOS; and Timothy G. Murray, MD, MBA, FACS
Disease features as well as individual patient needs and preferences should drive treatment choices.
By Antonio Capone Jr, MD
Although use of anti-VEGF agents seems safe in the general population, systemic safety concerns remain in at-risk patients.
By Karen Roman, Editor-in-Chief
With two distinct mechanisms of action, a new anti-integrin drug may be able to treat multiple targets across a range of conditions.
By Baruch D. Kuppermann, MD, PhD
When it comes to managing patients with diabetic macular edema, embracing new treatments requires planning.
By Szilárd Kiss, MD
An in-depth look at a complement-targeted therapy.
By Karen Roman, Editor-in-Chief
If approved by the FDA, a new anti-VEGF agent could provide physicians with an alternative treatment for neovascular AMD.